Market Place
Sourcing Support
RegeneRx Effects Reverse Stock Split and Terminates SEC Reporting Obligations
15 Aug 2023 //
PR NEWSWIRE
RegeneRx Receives Stockholder Approval for Reverse Stock Split
07 Aug 2023 //
PR NEWSWIRE
RegeneRx To Extend Consent Solicitation Vote
01 Aug 2023 //
PR NEWSWIRE
First Patient Enrolled into Phase 3 Neurotrophic Keratitis Trial with RGN-259
13 Apr 2023 //
PR NEWSWIRE
RegeneRx Issues Letter To Stockholders
11 Apr 2023 //
PR NEWSWIRE
Publication of RGN-259 Ph3 Trial Results in Patients Neurotrophic Keratopathy
03 Jan 2023 //
PR NEWSWIRE
RegeneRx Licensee Submits Assessment to FDA for PIII Trial for Dry Eye Disease
24 Oct 2022 //
PRNEWSWIRE
RegeneRx Partner Submits Phase 3 Protocol for Neurotrophic Keratopathy (NK)
27 Sep 2022 //
PRNEWSWIRE
RegeneRx Issues 2022 Letter To Stockholders
22 Aug 2022 //
PRNEWSWIRE
RegeneRx Partner Signs LOI with Global Ophthalmology CRO for Two PIII Trials
18 Jul 2022 //
PRNEWSWIRE
RegeneRx Licensee to Expand Phase 3 Clinical Trial Program with RGN-259
22 Jun 2022 //
PRNEWSWIRE
T?4 Shows Potential as Combination Treatment for Diabetes-Induced Complications
04 May 2022 //
PRNEWSWIRE
RegeneRx Provides Regulatory Update Regarding RGN-259
02 Mar 2022 //
PRNEWSWIRE
RegeneRx Consultant to Receive Prestigious Award in Field of Health
11 Feb 2022 //
PRNEWSWIRE
RegeneRx Publishes Regulatory Update on RGN-259
12 Jan 2022 //
PRNEWSWIRE
RegeneRx Joint Venture Requests Pre-BLA Meeting with FDA For RGN-259
29 Nov 2021 //
PRNEWSWIRE
Clinical Results of RGN-259 for the Treatment of Neurotrophic Keratitis
29 Oct 2021 //
PRNEWSWIRE
New Research Demonstrates Thymosin Beta 4`s Potential Positive Effects
05 Oct 2021 //
PRNEWSWIRE
RegeneRx Licensee Acquired by Korean Biopharmaceutical Group
27 Sep 2021 //
PRNEWSWIRE
RegeneRx Issues Letter To Stockholders
22 Jul 2021 //
PRNEWSWIRE
RegeneRx Issues Letter To Stockholders
22 Jul 2021 //
PRNEWSWIRE
RegeneRx Issues Letter To Stockholders
22 Jul 2021 //
PRNEWSWIRE
RegeneRx Issues Letter To Stockholders
22 Jul 2021 //
PRNEWSWIRE
RegeneRx JV Updates RGN-259 Regulatory Progress for Dry Eye Syndrome
14 Jul 2021 //
PRNEWSWIRE
RegeneRx JV Updates RGN-259 Regulatory Progress for Dry Eye Syndrome
14 Jul 2021 //
PRNEWSWIRE
RegeneRx Biopharmaceuticals, Inc. Closes $2 Million Private Placement
01 Jul 2021 //
PR NEWSWIRE
RegeneRx Biopharmaceuticals, Inc. Announces $2 Million Private Placement
29 Jun 2021 //
PR NEWSWIRE
RegeneRx Biopharmaceuticals, Inc. Announces $2 Million Private Placement
28 Jun 2021 //
PR NEWSWIRE
RegeneRx Issues Update on ARISE-3 Trial
22 Mar 2021 //
PRNEWSWIRE
RegeneRx Reports Topline Results of ARISE-3 Dry Eye Trial
18 Mar 2021 //
PRNEWSWIRE
RegeneRx Comments on ARISE-3 Clinical Trial
26 Jan 2021 //
PRNEWSWIRE
RegeneRx Issues Year End Letter To Stockholders
22 Dec 2020 //
PRNEWSWIRE
Last Patient, Last Visit Completed in RegeneRx Phase 3 Dry Eye Clinical Trial
09 Nov 2020 //
PRNEWSWIRE
RegeneRx Joint Venture Enrolls Last Subject in Phase 3 Dry Eye Trial
28 Oct 2020 //
PRNEWSWIRE
RegeneRx Expects to Complete Short-Term Financing While Completion of Ph3
13 Oct 2020 //
PRNEWSWIRE
Research Suggests RegeneRx`s Thymosin Beta 4 May be Useful in Treating COVID-19
08 Sep 2020 //
BIOSPACE
RegeneRx Joint Venture Expects to Complete Phase 3 Dry Eye Trial by end of 2020
31 Aug 2020 //
REGENERX
RegeneRx Advisory on ARISE-3 Dry Eye Trial
02 Jun 2020 //
PRNEWSWIRE
RegeneRx Advisory on Reclassification of Thymosin Beta 4 from Drug to Biologic
27 May 2020 //
PRNEWSWIRE
RegeneRx Issues Advisory on ARISE-3 Dry Eye Trial
20 Apr 2020 //
PR NEWSWIRE
New Publication Describes Mechanism of Action for T?4 in Corneal Regeneration
02 Apr 2020 //
PRNEWSWIRE
RegeneRx Issues Advisory on Dry Eye Trial Amid COVID-19 Virus
18 Mar 2020 //
PRNEWSWIRE
